Premium
A new monitoring tool CLIP test for progression of oxaliplatin‐induced peripheral neuropathy: A multicenter prospective study
Author(s) -
Kamei Keiko,
Ohnishi Tadashi,
Nakata Ken,
Danno Katsuki,
Ohkawa Atsushi,
Miyake Yasuhiro,
Okazaki Satoshi,
Fukunaga Mutsumi,
Toyokawa Akihiro,
Hamada Tetsuhiro,
Shindoh Junichi,
Kanazawa Akiyoshi
Publication year - 2020
Publication title -
asia‐pacific journal of clinical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.73
H-Index - 29
eISSN - 1743-7563
pISSN - 1743-7555
DOI - 10.1111/ajco.13404
Subject(s) - oxaliplatin , peripheral neuropathy , medicine , peripheral , multicenter study , prospective cohort study , oncology , cancer , colorectal cancer , diabetes mellitus , randomized controlled trial , endocrinology
Oxaliplatin‐induced peripheral neuropathy (OIPN) is a common adverse events that can limit a patient's quality of life during/after chemotherapy. However, no appropriate methods have been established yet for monitoring the risk of progression of OIPN. Methods A simple assessment tool using gem clips, the CLIP test, was established and its performance in predicting the risk of progression to ≥grade 2 peripheral sensory neuropathy (CTCAE ver. 4.0) was investigated in patients receiving chemotherapy with oxaliplatin. Results Among 101 patients included in this study, 71 patients developed CTCAE ≥grade 1 peripheral neuropathy (grade 1, n = 67; grade 2, n = 4) at a median of 63 (range, 14–259) days after the start of treatment. Of the 67 patients with grade 1 peripheral neuropathy, 17 showed progression to ≥grade 2 neuropathy after a median interval of 84 (range, 21–246) days. Of these patients, 27 showed a positive result of the CLIP test at a median of 91 (range, 14–224) days, excluding one patient who already showed a positive result of the test at the baseline. Therefore, the risk ratio for the development of CTCAE ≥grade 2 peripheral neuropathy was 8.3 in the patients who showed a positive result on the CLIP test. Multivariate analysis confirmed that a positive results on the CLIP test was significantly correlated with the risk of future development of CTCAE ≥grade 2 peripheral neuropathy (odds ratio, 9.37; P = 0.002). Conclusion A positive result on the CLIP test predict is predictive of the risk of progression of OIPN during chemotherapy with oxaliplatin.